SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s launches PRAMIPEXOLE Dihydrochloride extended-release tablets in US

13 Aug 2015 Evaluate

Dr. Reddy’s Laboratories has launched PRAMIPEXOLE dihydrochloride extended-release tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg, a therapeutic equivalent generic version of MIRAPEX ER (pramipexole dihydrochloride) Extended-Release Tablets in the US market on August 11, 2015, following the approval by the United States Food & Drug Administration (USFDA).

The MIRAPEX ER brand and generic had US sales of approximately $48.3 Million MAT for the most recent twelve months ending in June 2015. Dr. Reddy’s PRAMIPEXOLE dihydrochloride extended-release tablets are available in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count sizes of 30.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.


Dr. Reddys Labs. Share Price

1384.05 37.80 (2.81%)
03-Jul-2026 13:17 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1909.60
Dr. Reddys Labs. 1384.05
Cipla 1464.55
Zydus Lifesciences 1129.45
Lupin 2466.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: